Sanofi (NASDAQ:SNY) Maintains "Buy" Rating Amidst New Drug Approvals

Deutsche Bank maintains a "Buy" rating for Sanofi (NASDAQ:SNY), adjusting the price target from EUR 110 to EUR 105.Sanofi achieves significant milestones with the approval of innovative medicines Myqorzo and Redemplo in China.The current stock price of $46.59 reflects a decrease of approximately 1.86%, with a year's trading range showing some volatility.Sanofi (NASDAQ:SNY) is a global healthcare leader engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company ...